GAS5 and non-small cell lung carcinoma: Several studies have indicated that lncRNA GAS5 sponged miR-34a to activate the mTOR/SIRT1 pathway, thereby restraining the progression of colorectal cancer [12], and upregulated lncRNA GAS5 reduced cisplatin resistance in non-small cell lung cancer [13].